ATE518887T1 - Anti-igsf4-antikörper und dessen verwendung - Google Patents

Anti-igsf4-antikörper und dessen verwendung

Info

Publication number
ATE518887T1
ATE518887T1 AT06714335T AT06714335T ATE518887T1 AT E518887 T1 ATE518887 T1 AT E518887T1 AT 06714335 T AT06714335 T AT 06714335T AT 06714335 T AT06714335 T AT 06714335T AT E518887 T1 ATE518887 T1 AT E518887T1
Authority
AT
Austria
Prior art keywords
igsf4
antibodies
igsf4 antibodies
Prior art date
Application number
AT06714335T
Other languages
English (en)
Inventor
Yasushi Akahori
Atsushi Sugioka
Nobuhiro Hayashi
Akihiko Takasaki
Kazuhiro Suzuki
Miwa Morita
Yoshikazu Kurosawa
Yoshitaka Iba
Mariko Sumitomo
Susumu Tsutsumi
Keiko Ogawa
Kazuki Matsuda
Chiho Muramatsu
Nobuhiro Takahashi
Sari Fujiyama
Masachika Azuma
Yoshinori Ukai
Kazuhiro Morishita
Original Assignee
Inst Antibodies Co Ltd
Yoshikazu Kurosawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Antibodies Co Ltd, Yoshikazu Kurosawa filed Critical Inst Antibodies Co Ltd
Application granted granted Critical
Publication of ATE518887T1 publication Critical patent/ATE518887T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
AT06714335T 2005-02-28 2006-02-22 Anti-igsf4-antikörper und dessen verwendung ATE518887T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005054624 2005-02-28
JP2006003195 2006-02-22

Publications (1)

Publication Number Publication Date
ATE518887T1 true ATE518887T1 (de) 2011-08-15

Family

ID=40382395

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06714335T ATE518887T1 (de) 2005-02-28 2006-02-22 Anti-igsf4-antikörper und dessen verwendung

Country Status (1)

Country Link
AT (1) ATE518887T1 (de)

Similar Documents

Publication Publication Date Title
DE602005003186D1 (de) Fluorkopolymer und dessen Verwendung
LTPA2016026I1 (lt) Anti-il-17 antikūnai
NO20080692L (no) SP35 antistoffer og anvendelse derav
ATE428710T1 (de) Substituierte phenylaminothiazole und ihre verwendung
AP2008004471A0 (en) Anti-Alpha2 Intergin antibodies and their uses
IL222922A (en) Antibodies against neurophilin-1 and their use
DK2222706T3 (da) Antibodies against human nkg2d and uses thereof
PT2343320T (pt) Anticorpos anti-gitr e as suas utilizações
IL184024A0 (en) Irta-5 antibodies and their uses
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
IL191820A0 (en) Anti-ox40l antibodies and methods using same
NO20071430L (no) Anti-OX4OL antistoffer
ATE531712T1 (de) Substituierte aryloxazole und ihre verwendung
IL178277A0 (en) Irta-5 antibodies and their uses
ATE511507T1 (de) Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten
DE602006018166D1 (de) Polyrotaxanhaltige lösung und verwendung davon
ATE493396T1 (de) Neue indazolcarboxamide und ihre verwendung
ATE547002T1 (de) Pestizide und ihre verwendung
DE602007006540D1 (de) Cyclopropancarboxylate und deren verwendung als pestizide
DE602006008025D1 (de) Amidverbindungen und deren verwendung
DE602005007866D1 (de) 1-phenyl- und 1-pyridylpyrazolderivate und deren verwendung als pestizide
AT508430A5 (de) Formbauteil und dessen verwendung
DE602006007777D1 (de) Reductase Gen und dessen Verwendung
DE112005001260A5 (de) Antigen des PM-2 Antikörpers und dessen Verwendung
ATE518887T1 (de) Anti-igsf4-antikörper und dessen verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties